European Gene Therapy Markets


USD 4,950.00

* Required Fields

USD 4,950.00


Be the first to review this product

Cell Therapies; Gene Therapies: corrective gene delivery, therapeutic gene delivery, ribozymes, antisense, prodrug + enzyme delivery. Not DNA vaccines (therapeutic or prophylactic). In relation to the European market; in particular, the way in which these therapies would be applied to European therapeutic methodology.

Table of Contents

European Gene Therapy Markets, Executive SummaryMarket OverviewIntroduction and PresentationEuropean Gene Therapy Markets, Gene Therapy OverviewA New Definition of MedicineA Brief HistoryMarket DefinitionThe European PerspectiveGlossary of TermsTechnology OverviewViral Vector TechnologyNon-Viral Vector TechnologyGene-Related Therapeutic TechnologyEuropean Gene Therapy Markets, Strategic Assessment of the European Gene Therapy MarketsCorporate StrategyDefining the Corporate StrategyCommercial StrategyDevelopment StrategyPatent StrategyPublic Relations StrategyProduct StrategyGaining a Premium PriceChoosing the Right IndicationsGetting the Product LaunchedMarket Engineering Research for the Total European Gene Therapy MarketsMarket OverviewMarket Engineering Research Measurement SystemR and D FocusSelected European Gene Therapy CompaniesCompetitive OverviewForecasts for the Total Gene Therapy MarketMarket DriversMarket RestraintsMarket Engineering Revenue ForecastsAssumptions for Launch Date ForecastsAssumptions for Treatable Population and Revenue ForecastsRevenue Trends by Product TypeMarket Engineering Research for the European Cancer Gene Therapy MarketMarket OverviewIntroduction to Cancer Gene TherapyHead and Neck CancerNSC Lung CancerBreast CancerGliomaPancreatic CancerColorectal CancerForecasts for the Cancer Gene Therapy MarketMarket DriversMarket RestraintsForecasts for the Total Cancer Gene Therapy MarketSelected Products in Early-Stage DevelopmentIntrogen Therapeutics: AdvexinOnyx Pharmaceuticals: ONYX-015Ark Therapeutics: EG009Targeted Genetics: tgDCC-E1AGenvec: TNFeradeRibozyme Pharmaceuticals: AngiozymeMarket Engineering Research for the European Vascular Diseases Gene Therapy MarketMarket OverviewIntroduction to Vascular Disease Gene TherapyIschaemic Heart Disease and Treatment OverviewPeripheral Vascular Disease and Treatment OverviewEpidemiology and the Potentially Treatable PopulationForecasts for the Vascular Diseases Gene Therapy MarketMarket DriversMarket RestraintsForecast for the Total Vascular Diseases Gene Therapy MarketSelected Products in Early-Stage DevelopmentCollateral Therapeutics/Schering AG: GenerxCollateral Therapeutics/Schering AG: GenvascorFornix Biosciences: phVEGFAventis: NV1FGFGenVec: BioBypassArk Therapeutics: Trinam (EG004)Market Engineering Research for the European Monogenic Disease MarketMarket OverviewSummaryCystic Fibrosis and Treatment OverviewSCID and Treatment OverviewHaemophilia B and Treatment OverviewForecasts for the Monogenic Disease Gene Therapy MarketMarket DriversMarket RestraintsForecasts for the Total Monogenic Diseases Gene Therapy MarketSelected Products in Early Stage TrialsTargeted Genetics: tgAAVCFAVAX/Genopoeitic: SCIDAvigen: Coagulin BEuropean Gene Therapy Markets, Market Engineering AwardsFrost & Sullivan 2002 ME Awards for Gene TherapyMarket Engineering Awards 2002Business Development Strategy Award: AventisCompetitive Strategy Award: Schering AG with Collateral TherapeuticsProduct Innovation Award: Targeted Genetics

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.